Researchers Marcus Schmidt, Hans-Anton Lehr, and Katrin Almstedt discuss the impact of HER2 in breast cancer prognosis and treatment. They challenge conventional beliefs by exploring the responsiveness of HER2-low and HER2-zero tumors to Trastuzumab-based therapies.

Researcher Kazuhiro Kitajima discusses a study comparing FDG-PET/CT and CT for evaluating tumor response in patients with unresectable mesothelioma. The study focuses on response rates, survival outcomes, and imaging modalities accuracy in treatment evaluation.

Researchers Kevin C. Ma, Esther Mena, Liza Lindenberg, Nathan S. Lay, and others introduce an AI tool for attenuation-corrected PET images in prostate cancer imaging, reducing reliance on CT scans and patient radiation exposure. The deep learning algorithm successfully generates AC PET images, enhancing diagnostic confidence and patient care.

Researchers from Leiden University discuss targeting ABC transporters in pancreatic ductal carcinoma (PDAC) and the impact on chemotherapy resistance. They highlight ABCB1's role in multidrug resistance and poor prognosis. The podcast explores the potential of targeting ABCB1 as a therapeutic strategy to overcome drug resistance in patients.

Research paper explores the combination of TAS-102 and Regorafenib for treating gastrointestinal cancers with promising anti-tumor effects in preclinical studies, providing a potential new treatment approach for advanced GI cancers.

Laurène Fenwarth, a molecular researcher from the University of Lille, and Nicolas Duployez, an expert in acute myeloid leukemias from CHU Lille, share their insights on the evolving role of genomics in cancer treatment. They discuss how molecular and cytogenetic analyses reveal new mutations that aid in classifying acute myeloid leukemias and myelodysplastic syndromes. Despite significant advancements, 15% of AML cases remain genetically unclassifiable. Their discussion highlights the need for continued research and innovative bioinformatics to tackle these challenges.

Researchers discuss a novel therapeutic strategy for prostate cancer involving the depletion of cysteine to induce oxidative stress and DNA damage, enhancing the efficacy of DNA repair targeted and immune checkpoint blockade therapies.

Duke University researchers discuss leveraging gold nanostars for precision laser interstitial thermal therapy to improve treatment for brain tumors. They explore the limitations of current methods and how utilizing nanostars can enhance precision, efficiency, and safety in the procedure.

Exploring the challenges of using dual immunotherapies in HR+/HER2-negative breast cancer patients, focusing on amplifying tumor-infiltrating lymphocytes through dual checkpoint inhibition before surgery and chemotherapy. Highlighting the importance of biomarkers like PDL1 expression and tumor mutation burden in improving treatment outcomes and reducing toxicity.

Researchers from Schulich School of Medicine discuss the role of CEA, CA-125, and CA19-9 as adjuncts in NSCLC management. They analyze associations with radiographic responses and clinical outcomes in NSCLC patients. The study provides evidence for the clinical use of these tumor markers in guiding treatment decisions.